🔥🐔 BizChicken 🐔🔥

Companies Similar to Black Diamond Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. logo
Market Cap: Lowest
Employees: Lowest

BRTX-100

Bio Restorative Therapies, Inc., a life sciences company, focuses on developing regenerative medicine products and therapies primarily involving adult stem cells to treat disc/spine disease and metabolic disorders.

Tags: biotechnology, cell therapy, disc/spine disease, metabolic disorders, regenerative medicine, stem cells

Symbol: BRTX

Recent Price: $1.44

Industry: Biotechnology

CEO: Mr. Lance Alstodt

Sector: Healthcare

Employees: 11

Address: 40 Marcus Drive, Melville, NY 11747

Phone: 631 760 8100

Last updated: 2024-12-31

Disc Medicine, Inc.

Disc Medicine, Inc. logo
Market Cap: High
Employees: Low

Therapeutic candidates for hematologic diseases

Disc Medicine, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel treatments for patients with serious hematologic diseases. The company's portfolio addresses hematologic diseases by targeting key biological pathways in red blood cell biology.

Tags: biotechnology, hematologic diseases, heme biosynthesis, iron homeostasis, red blood cell biology

Symbol: IRON

Recent Price: $61.60

Industry: Biotechnology

CEO: Dr. John D. Quisel Esq., J.D., Ph.D.

Sector: Healthcare

Employees: 78

Address: 321 Arsenal Street, Watertown, MA 02472

Phone: 617 674 9274

Last updated: 2024-12-31

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

LB-100 series and LB-200 series

Lixte Biotechnology Holdings, Inc. is a drug discovery company leveraging biomarker technology to develop enzyme-targeting drugs for cancer, vascular, metabolic, hereditary, and neurodegenerative diseases.

Tags: biomarker technology, biotechnology, cancer treatment, drug discovery, enzyme targets

Symbol: LIXT

Recent Price: $2.00

Industry: Biotechnology

CEO: Mr. Bastiaan van der Baan M.Sc.

Sector: Healthcare

Employees: 3

Address: 680 East Colorado Boulevard, Pasadena, CA 91101

Phone: 631 830 7092

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. logo
Market Cap: Lowest
Employees: Low

TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.

Tags: CNS, autoimmunity, biopharmaceutical, cancer, immunology, infectious disease, rare disease, therapeutics

Symbol: TNXP

Recent Price: $0.36

Industry: Biotechnology

CEO: Dr. Seth Lederman M.D.

Sector: Healthcare

Employees: 103

Address: 26 Main Street, Chatham, NJ 07928

Phone: 862 799 8599

Last updated: 2024-12-31

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

AVTX-002, AVTX-007, AVTX-801

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

Tags: clinical trials, immuno-oncology, immunology, precision medicine, rare genetic diseases, therapeutics

Symbol: AVTX

Recent Price: $7.80

Industry: Biotechnology

CEO: Dr. Garry A. Neil M.D.

Sector: Healthcare

Employees: 19

Address: 540 Gaither Road, Rockville, MD 20850

Phone: 410 522 8707

Leadership

  • Garry A. Neil, MD, Chairman of the Board and Chief Executive Officer
  • Mittie Doyle, MD, FACR, Chief Medical Officer
  • Chris Sullivan, Chief Financial Officer
  • Paul Varki, Chief Legal Officer
  • Lisa Hegg PhD, Senior Vice President, Program Management and Corporate Infrastructure and Clinical Operations
  • Colleen Matkowski, Senior Vice President, Global Regulatory Affairs and Quality Assurance
  • Dino C. Miano, PhD, Senior Vice President, CMC and Technical Operations
  • June Almenoff, MD, PhD, President and Chief Medical Officer
  • Mitchell Chan, Chief Financial Officer
  • Jonathan Goldman, MD, CEO
  • Aaron Kantoff, Managing Partner
  • Gilla Kaplan, PhD, Independent Director
  • Samantha Truex, CEO

Last updated: 2024-12-31

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

BDTX-189, BDTX-1535, BDTX-4933

Black Diamond Therapeutics, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for patients with genetically defined tumors. The company focuses on creating irreversible small molecule inhibitors to target specific oncogenic proteins.

Tags: biotechnology, cancer treatment, genetically defined tumors, small molecule inhibitors

Symbol: BDTX

Recent Price: $2.15

Industry: Biotechnology

CEO: Dr. Mark A. Velleca M.D., Ph.D.

Sector: Healthcare

Employees: 54

Address: One Main Street, Cambridge, MA 02142

Phone: 617 252 0848

Leadership

  • Ali Behbahani, M.D., Co-Head of Healthcare, NEA
  • Shannon Campbell, Executive Vice President and Chief Commercial Officer, Merus
  • Kapil Dhingra, M.D., Former Head, Roche Oncology Development
  • Samarth (Sam) Kulkarni, Ph.D., CEO, CRISPR Therapeutics AG
  • Garry E. Menzel, Ph.D., Operating Partner, GHO Capital Partners LLP
  • Prakash Raman, Ph.D., CEO of InduPro, Inc.
  • Mark A. Velleca, M.D., Ph.D., CEO and Board Chair

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Biomerica, Inc.

Biomerica, Inc. logo
Market Cap: Lowest
Employees: Low

diagnostic and therapeutic products

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures, and markets diagnostic and therapeutic products for medical conditions and diseases worldwide, focusing on gastrointestinal diseases, food intolerances, and diabetes.

Tags: biomedical, diabetes, diagnostic, food intolerances, gastrointestinal, therapeutic

Symbol: BMRA

Recent Price: $0.31

Industry: Medical - Devices

CEO: Mr. Zackary S. Irani

Sector: Healthcare

Employees: 64

Address: 17571 Von Karman Avenue, Irvine, CA 92614

Phone: 949 645 2111

Last updated: 2024-12-31

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

BDC-1001

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology agents that target tumor cells for immune system elimination.

Tags: HER2, biotechnology, cancer treatment, clinical-stage, immuno-oncology

Symbol: BOLT

Recent Price: $0.57

Industry: Biotechnology

CEO: Mr. William P. Quinn

Sector: Healthcare

Employees: 100

Address: 900 Chesapeake Drive, Redwood City, CA 94063

Phone: 650 665 9295

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Ik T-148009

Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.

Tags: Cancer Treatment, Neurological Disorders, Parkinson's Disease, Pharmaceutical, Therapeutics

Symbol: IKT

Recent Price: $3.24

Industry: Biotechnology

CEO: Dr. Milton H. Werner Ph.D.

Sector: Healthcare

Employees: 8

Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339

Phone: 678 392 3419

Leadership

  • Milton H. Werner, Ph.D., President and CEO
  • C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
  • Garth Lees-Rolfe, CPA, Chief Financial Officer
  • Dan Williams, Controller
  • Terence Kelly, Ph.D., Medicinal Chemistry Consultant
  • Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
  • Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
  • Roberto Bellini, Managing Partner at BSQUARED Capital
  • Dennis Berman, Serial Entrepreneur
  • David Canner, Ph.D., Partner at Soleus Capital
  • Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
  • Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
  • Amit Munshi, Chief Executive Officer of Orna Therapeutics

Last updated: 2024-12-31

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

INT230-6

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of cancer drugs for treating solid tumors. Their lead product, INT230-6, is undergoing Phase 2 trials for various cancers and is being tested in collaborations with major pharmaceutical companies.

Tags: biotechnology, cancer treatment, clinical trials, collaboration, solid tumors

Symbol: INTS

Recent Price: $1.82

Industry: Biotechnology

CEO: Mr. Lewis H. Bender M.A., M.B.A., M.S.

Sector: Healthcare

Employees: 5

Address: 61 Wilton Road, Westport, CT 06880

Phone: 203 221 7381

Leadership

  • Lewis H. Bender, M.S., M.A., M.B.A., Founder and CEO
  • Joseph Talamo, CPA, Chief Financial Officer
  • James M. Ahlers, Executive Vice President
  • Brian Schwartz, MD, Executive VP, Clinical Development
  • John Wesolowski, CPA, MBA, Principal Accounting Officer and Controller
  • Kimberly A. Guedes, RN, MBA, Vice President of Clinical Operations
  • Doranne Frano, Regulatory Affairs and Quality Control
  • Daniel J. Donovan, Board Member and Chief Executive Officer
  • Tom Dubin, Board Member
  • Mark A. Goldberg, MD, Board Member
  • Emer Leahy, Ph.D., Board Member

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TTX-MC138

Trans Code Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs and diagnostics for treating metastatic disease. Their lead product, TTX-MC138, is aimed at metastatic cancer treatment, along with a range of other therapeutic platforms targeting cancer through innovative RNA- and CRISPR-based technologies.

Tags: CRISPR technology, RNA-based therapy, biopharmaceutical, cancer treatment, metastatic disease

Symbol: RNAZ

Recent Price: $3.76

Industry: Biotechnology

CEO: Mr. Thomas A. Fitzgerald M.B.A.

Sector: Healthcare

Employees: 10

Address: 6 Liberty Square, Boston, MA 02109

Phone: 857-837-3099

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Denali Therapeutics Inc.

Denali Therapeutics Inc. logo
Market Cap: High
Employees: Medium

BIIB122/DNL151

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. Its pipeline includes treatments for Parkinson's disease, hunter syndrome, ALS, multiple sclerosis, and Alzheimer's disease. It collaborates with companies such as Takeda Pharmaceutical Company and Genentech, Inc.

Tags: ALS, Alzheimer's disease, Parkinson's disease, biopharmaceutical, hunter syndrome, multiple sclerosis, neurodegenerative diseases

Symbol: DNLI

Recent Price: $20.24

Industry: Biotechnology

CEO: Dr. Ryan J. Watts Ph.D.

Sector: Healthcare

Employees: 364

Address: 161 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 866 8548

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31